cycling glp 1 JCI Insight Weighing the risk of GLP-1
Description
NDAs in China are planned, while partner Kailera advances global development.
Research hasn't yet shown the health impacts of cycling on and off the drugs.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may have a welcome benefit in addition to weight loss and glycemic control, with new data pre...
New obesity drugs that were designed to treat diabetes and obesity are increasingly being used off-label by people without these conditions to achieve slimness and social approval rather than health gains
When you stop matters and why matters more
